Skip to main content

Table 1 HLA associations with adverse drug reactions

From: Pharmacogenomics of adverse drug reactions

Type of toxicity

Drug

HLA allele

Type of study

Approximate odds ratio

Reference(s)

Hypersensitivity

Abacavir

B*57:01

Candidate gene

800

[25, 26]

Liver injury

Amoxicillin-clavulanate

DRB1*15:01-DQB1*06:02 A*02:01

Candidate gene and GWA

3 2.3

[14, 15, 72, 93, 94]

 

Ximelagatran

DRB1*07:01-DQA1*02:01

GWA

Not available (P = 6.0 × 10-6)

[95]

 

Ticlopidine

A*33:03

Candidate gene

13

[96]

 

Flucloxacillin

B*57:01

GWA

80

[17]

 

Lumiracoxib

DRB1*15:01-DQB1*06:02

GWA

5.3

[97]

 

Lapatinib

DQA1*02:01

GWA and candidate gene

9

[98]

 

Nevirapine

DRB1*01

Candidate gene

3

[35, 99]

SJS and TEN

Carbamazepine

B*15:02

Candidate gene

895

[21]

Various skin reactions, including SJS and TEN

Carbamezepine

A*31:01

GWA

12

[23, 24]

Various skin reactions including SJS and TEN

Allopurinol

B*58:01

Candidate gene

400

[29]

Various skin reactions

Nevirapine

B*35:05

Cw*8

Cw*04

Candidate gene and GWA

30

15

2.5

[33, 34]

[31, 32]

[35]

  1. GWA, genome-wide association; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.